Biohaven Ltd

NYSE: BHVN
$53.09
-$0.65 (-1.2%)
Closing Price on November 7, 2024

BHVN Stock Chart and Intraday Price

BHVN Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 215 CHURCH STREET, NEW HAVEN, CT, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 4,041.47M USD
Shares Outstanding 81,580,000
Biohaven Ltd is a biopharmaceutical company based in New Haven, Connecticut, dedicated to advancing treatments in immunology, neuroscience, and oncology. With a robust pipeline, Biohaven is actively working on developing therapies for a range of conditions including neurological disorders, spinal muscular atrophy, obesity, epilepsy, bipolar disorder, major depressive disorder, migraines, neuropathic pain, Alzheimer's, Parkinson’s disease, rheumatoid arthritis, and various cancers. The company collaborates with prestigious institutions like Yale University and AstraZeneca to bring innovative solutions from the lab to the patients who need them.

BHVN Articles

Initial public offerings and a secondary offering inspired insiders to pick up some shares of these biotech companies and others.
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Biohaven, Edwards Lifesciences, Enphase Energy, Halliburton, Invesco, Liberty Energy, Mattel, Netflix, Permian Resources,...
Wednesday’s additional top analyst upgrades and downgrades were on Ally Financial, Baker Hughes, Biohaven, Biogen, Bumble, Canopy Growth, Corning, Discover Financial Services, Match, Roku and more.
Friday's additional top analyst upgrades and downgrades were on Applied Materials, Dick’s Sporting Goods, Foot Locker, HP, Meta Platforms, Occidental Petroleum and more.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Biohaven Pharmaceutical, SmileDirectClub, Squarespace and Victoria’s Secret.